Form 4: Guided Therapeutics Director Acquires Shares Through Dividend Conversion

Richard P. Blumberg, a director of Guided Therapeutics Inc., acquired 170,563 shares of common stock through the conversion of accrued dividends on Series E preferred stock.

Summary

• On August 21, 2024, Richard P. Blumberg, a director of Guided Therapeutics Inc., acquired 170,563 shares of common stock.
• The acquisition was a result of the payment of accrued dividends on the reporting individual's Series E preferred stock.
• The conversion price was $0.1093 per share.
• Following the transaction, Blumberg beneficially owns 6,289,725 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, as it simply reports a factual event.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This specific filing indicates a director receiving shares through a pre-existing agreement (dividend conversion), which is a common practice.

Key Dates

Keywords

Form 4, Beneficial Ownership, Richard P. Blumberg, Guided Therapeutics Inc., GTHP, Director, Dividend Conversion, Series E Preferred Stock, Common Stock